JAK1 and COVID-19: The JAK1/JAK2 inhibitor, baricitinib, was designed to treat inflammatory diseases and is currently licensed for the treatment of rheumatoid arthritis, severe atopic dermatitis, severe alopecia areata (45–49) and recently received emergency FDA approval for COVID-19 (50).